Phase 3 data show that ocrelizumab (Ocrevus) may delay the progression of disability, such as the need for a wheelchair, in patients with primary progressive multiple sclerosis (PPMS).
Genentech, a member of the Roche Group, shared new analyses of phase 3 data for ocrelizumab (Ocrevus) that show that the drug may delay the progression of disability, such as the need for a wheelchair, in patients with primary progressive multiple sclerosis (PPMS).
The company announced that new ocrelizumab data will be presented this weekend at the 4th Congress of the European Academy of Neurology (EAN) in Lisbon, Portugal.
“To a person living with primary progressive MS, for whom disability accumulates twice as fast as in relapsing MS, seven more years without the need for a wheelchair could extend the time they can live independently in their home, continue working or looking after their families,” said Helmut Butzkueven, Professor and Chair of MS and Neuroimmunology Research at Central Clinical School, Monash University, Head of MS and Neuroimmunology Service at Alfred Health and Director of MS Service at Eastern Health.
Click to continue reading on MD Magazine.
The Clinical Focus condition center at NeurologyLive, Specialty Pharmacy Times' new sister site, provides even more extensive coverage from the multiple sclerosis space, as well as updates from the field’s most prominent conferences.